# Ruiming Xinyao

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ruiming-xinyao

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Latest round: Series B (Apr 6, 2022)
- Investors on record: 10

## About

Based in Suzhou, China, and established in 2018, Ruiming Xinyao operates as a pharmaceutical company that focuses on developing small molecule new drugs for the treatment of ophthalmic diseases. The company's team members are from pharmaceutical companies, such as Novartis and Alcon, who have experience in new drugs development and drug launches. 

The company's products lines covered the fields of ophthalmology vascular lesions and ophthalmology neurological lesions. The ophthalmology vascular lesions include Age-related wet macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema. The ophthalmology neurological lesions include glaucoma. The form of drug delivery is eye drop, which replaced the previous injection into the vitreous.  

The company plans to use the series B funding to apply for the Investigational New Drug (IND), product clinical testing, and introduce new projects.

## Funding rounds

- Series B, Apr 6, 2022 — Jinding Capital, Huarun Zhengda life Science Fund
- Series A, Jun 15, 2021 — TigerYeah Capital, Ascendin Fund, HM Capital
- Series A, Dec 7, 2020 — Korea Investment Partners, Sangel Capital, Topping Capital, TigerYeah Capital, Ascendin Fund
- Angel, May 11, 2018 — Shanghai Jianyi Private Equity Fund Management, Legend Star

## Investors

- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Angel
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Angel
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series A
- Topping Capital (https://capitalatlas.ai/funds/topping-capital) — Series A
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- Ascendin Fund (https://capitalatlas.ai/funds/ascendin-fund) — Series A
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series A
- Jinding Capital (https://capitalatlas.ai/funds/jinding-capital) — Series B
- Huarun Zhengda life Science Fund — Series B